The pharmaceutical industry is one of the countless users of AI. Costs and development times for new drugs are being drastically reduced, old barriers to market entry are removed and new ones erected.
No wonder most share prices have risen this year. Investor favour however is mercilessly selective: while Eli Lilly and Novo Nordisk have been catapulted to dizzying projected P/E ratios of around 30, Brystol Myers Squibb shares, among others, are bobbing around at potential bargain prices of less than a quarter of that or around seven expected annual profits.
Our current sector analysis shows the key figures of the world’s most important players, the winners and losers and the most suitable shares for different investment styles.